VHL and renal cell carcinoma: Recently, the understanding of accumulation of HIF-2α within the cell as a result of VHL inactivation has led to the development of belzutifan, the first oral HIF-2α inhibitor approved by the FDA in 2021 for treatment of adult patients with VHL associated RCC, CNS hemangioblastomas, or PNETs, not requiring immediate surgery.